Tempus announces nine abstracts accepted for presentation at the 2024 society for immunotherapy of cancer annual meeting

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the society for immunotherapy of cancer's (sitc) 39th annual meeting, which convenes in houston, texas, from november 6-10, 2024. “presenting our latest research is a vital opportunity to showcase the advancements tempus is making in harnessing the power of data and ai to drive im.
TEM Ratings Summary
TEM Quant Ranking